Evaxion has announced the presentation of preclinical data regarding its vaccine candidate for acute myeloid leukemia (AML). The data showcases the potential efficacy and safety of the vaccine in early-stage trials. This development marks a significant step in the company's efforts to address AML, a type of cancer that affects the blood and bone marrow. Further research and clinical trials will be necessary to evaluate the candidate's effectiveness in human subjects.
Related Articles
Don't miss out on breaking stories and in-depth articles.